Suicide gene therapy for premalignant disease

A new strategy for the treatment of intraepithelial neoplasia

Z. Sandalon, N. E. Fusenig, Jane McCutcheon, L. B. Taichman, J. A. Garlick

Research output: Contribution to journalArticle

Abstract

The potential of gene therapy to treat premalignant disease or recurrent cancer has not been investigated. The goal of the present investigation was to explore the efficacy of pro-drug-mediated, suicide gene therapy as a strategy to treat incipient neoplasia in stratified squamous epithelium. To test this strategy, a tissue model of premalignancy was generated by mixing normal human keratinocytes (NHK) that express the bacterial cytosine deaminase gene (CD) with premalignant keratinocytes which have been genetically marked with the bacterial gene for β-galactosidase (II-4-β-gal) in skin-like organotypic cultures. Preliminary studies in monolayer cultures demonstrated that CD-transduced NHK (NHK/CD) efficiently expressed the transgene and deaminated the pro-drug 5-fluorocytosine (5FC) to the toxic product 5-fluorouracil (5FU). The capacity of NHK/CD to kill II-4-β-gal cells through bystander effect was assayed in both submerged culture and in the organotypic model of premalignancy. In submerged cultures, it was found that CD-mediated killing of II-4-β-gal cells did not require cell-cell contact and that the LD50 of 5FC for efficient bystander killing of 11-4-β-gal was 0.5 mM. When this concentration of pro-drug was used in organotypic cultures, a significant number of dysplastic II-4-β-gal cells were eliminated from the tissue. Bystander killing of II-4-β-gal cells was related to the number of NHK/CD present. These findings demonstrated that potentially malignant keratinocytes could be eliminated from a dysplastic tissue through activation of pro-drug and killing of adjacent cells through the bystander effect. By establishing and in vitro model to eliminate premalignant cells using suicide gene therapy, these studies provide a new approach for the treatment of incipient cancer as it develops, thereby preventing invasive disease.

Original languageEnglish (US)
Pages (from-to)232-238
Number of pages7
JournalGene Therapy
Volume8
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Cytosine Deaminase
Genetic Therapy
Suicide
Keratinocytes
Prodrugs
Neoplasms
Bystander Effect
Genes
Flucytosine
Therapeutics
Galactosidases
Bacterial Genes
Poisons
Lethal Dose 50
Transgenes
Fluorouracil
Epithelium
Skin

Keywords

  • Bystander effect
  • Cytosine deaminase
  • Organotypic culture
  • Premalignant disease
  • Suicide gene therapy

ASJC Scopus subject areas

  • Genetics

Cite this

Suicide gene therapy for premalignant disease : A new strategy for the treatment of intraepithelial neoplasia. / Sandalon, Z.; Fusenig, N. E.; McCutcheon, Jane; Taichman, L. B.; Garlick, J. A.

In: Gene Therapy, Vol. 8, No. 3, 2001, p. 232-238.

Research output: Contribution to journalArticle

Sandalon, Z. ; Fusenig, N. E. ; McCutcheon, Jane ; Taichman, L. B. ; Garlick, J. A. / Suicide gene therapy for premalignant disease : A new strategy for the treatment of intraepithelial neoplasia. In: Gene Therapy. 2001 ; Vol. 8, No. 3. pp. 232-238.
@article{d255a3aa29b046d1b5644f6b435dc5e2,
title = "Suicide gene therapy for premalignant disease: A new strategy for the treatment of intraepithelial neoplasia",
abstract = "The potential of gene therapy to treat premalignant disease or recurrent cancer has not been investigated. The goal of the present investigation was to explore the efficacy of pro-drug-mediated, suicide gene therapy as a strategy to treat incipient neoplasia in stratified squamous epithelium. To test this strategy, a tissue model of premalignancy was generated by mixing normal human keratinocytes (NHK) that express the bacterial cytosine deaminase gene (CD) with premalignant keratinocytes which have been genetically marked with the bacterial gene for β-galactosidase (II-4-β-gal) in skin-like organotypic cultures. Preliminary studies in monolayer cultures demonstrated that CD-transduced NHK (NHK/CD) efficiently expressed the transgene and deaminated the pro-drug 5-fluorocytosine (5FC) to the toxic product 5-fluorouracil (5FU). The capacity of NHK/CD to kill II-4-β-gal cells through bystander effect was assayed in both submerged culture and in the organotypic model of premalignancy. In submerged cultures, it was found that CD-mediated killing of II-4-β-gal cells did not require cell-cell contact and that the LD50 of 5FC for efficient bystander killing of 11-4-β-gal was 0.5 mM. When this concentration of pro-drug was used in organotypic cultures, a significant number of dysplastic II-4-β-gal cells were eliminated from the tissue. Bystander killing of II-4-β-gal cells was related to the number of NHK/CD present. These findings demonstrated that potentially malignant keratinocytes could be eliminated from a dysplastic tissue through activation of pro-drug and killing of adjacent cells through the bystander effect. By establishing and in vitro model to eliminate premalignant cells using suicide gene therapy, these studies provide a new approach for the treatment of incipient cancer as it develops, thereby preventing invasive disease.",
keywords = "Bystander effect, Cytosine deaminase, Organotypic culture, Premalignant disease, Suicide gene therapy",
author = "Z. Sandalon and Fusenig, {N. E.} and Jane McCutcheon and Taichman, {L. B.} and Garlick, {J. A.}",
year = "2001",
doi = "10.1038/sj.gt.3301344",
language = "English (US)",
volume = "8",
pages = "232--238",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Suicide gene therapy for premalignant disease

T2 - A new strategy for the treatment of intraepithelial neoplasia

AU - Sandalon, Z.

AU - Fusenig, N. E.

AU - McCutcheon, Jane

AU - Taichman, L. B.

AU - Garlick, J. A.

PY - 2001

Y1 - 2001

N2 - The potential of gene therapy to treat premalignant disease or recurrent cancer has not been investigated. The goal of the present investigation was to explore the efficacy of pro-drug-mediated, suicide gene therapy as a strategy to treat incipient neoplasia in stratified squamous epithelium. To test this strategy, a tissue model of premalignancy was generated by mixing normal human keratinocytes (NHK) that express the bacterial cytosine deaminase gene (CD) with premalignant keratinocytes which have been genetically marked with the bacterial gene for β-galactosidase (II-4-β-gal) in skin-like organotypic cultures. Preliminary studies in monolayer cultures demonstrated that CD-transduced NHK (NHK/CD) efficiently expressed the transgene and deaminated the pro-drug 5-fluorocytosine (5FC) to the toxic product 5-fluorouracil (5FU). The capacity of NHK/CD to kill II-4-β-gal cells through bystander effect was assayed in both submerged culture and in the organotypic model of premalignancy. In submerged cultures, it was found that CD-mediated killing of II-4-β-gal cells did not require cell-cell contact and that the LD50 of 5FC for efficient bystander killing of 11-4-β-gal was 0.5 mM. When this concentration of pro-drug was used in organotypic cultures, a significant number of dysplastic II-4-β-gal cells were eliminated from the tissue. Bystander killing of II-4-β-gal cells was related to the number of NHK/CD present. These findings demonstrated that potentially malignant keratinocytes could be eliminated from a dysplastic tissue through activation of pro-drug and killing of adjacent cells through the bystander effect. By establishing and in vitro model to eliminate premalignant cells using suicide gene therapy, these studies provide a new approach for the treatment of incipient cancer as it develops, thereby preventing invasive disease.

AB - The potential of gene therapy to treat premalignant disease or recurrent cancer has not been investigated. The goal of the present investigation was to explore the efficacy of pro-drug-mediated, suicide gene therapy as a strategy to treat incipient neoplasia in stratified squamous epithelium. To test this strategy, a tissue model of premalignancy was generated by mixing normal human keratinocytes (NHK) that express the bacterial cytosine deaminase gene (CD) with premalignant keratinocytes which have been genetically marked with the bacterial gene for β-galactosidase (II-4-β-gal) in skin-like organotypic cultures. Preliminary studies in monolayer cultures demonstrated that CD-transduced NHK (NHK/CD) efficiently expressed the transgene and deaminated the pro-drug 5-fluorocytosine (5FC) to the toxic product 5-fluorouracil (5FU). The capacity of NHK/CD to kill II-4-β-gal cells through bystander effect was assayed in both submerged culture and in the organotypic model of premalignancy. In submerged cultures, it was found that CD-mediated killing of II-4-β-gal cells did not require cell-cell contact and that the LD50 of 5FC for efficient bystander killing of 11-4-β-gal was 0.5 mM. When this concentration of pro-drug was used in organotypic cultures, a significant number of dysplastic II-4-β-gal cells were eliminated from the tissue. Bystander killing of II-4-β-gal cells was related to the number of NHK/CD present. These findings demonstrated that potentially malignant keratinocytes could be eliminated from a dysplastic tissue through activation of pro-drug and killing of adjacent cells through the bystander effect. By establishing and in vitro model to eliminate premalignant cells using suicide gene therapy, these studies provide a new approach for the treatment of incipient cancer as it develops, thereby preventing invasive disease.

KW - Bystander effect

KW - Cytosine deaminase

KW - Organotypic culture

KW - Premalignant disease

KW - Suicide gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0035110754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035110754&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301344

DO - 10.1038/sj.gt.3301344

M3 - Article

VL - 8

SP - 232

EP - 238

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 3

ER -